- Home
- JAGX vs TENX Comparison
JAGX vs TENX Comparison
Compare JAGX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- TENX
- Stock Information
- Founded
- JAGX 2013
- TENX 1967
- Country
- JAGX United States
- TENX United States
- Employees
- JAGX N/A
- TENX N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- TENX Health Care
- Exchange
- JAGX Nasdaq
- TENX Nasdaq
- Market Cap
- JAGX 3.4M
- TENX 21.6M
- IPO Year
- JAGX N/A
- TENX N/A
- Fundamental
- Price
- JAGX $2.40
- TENX $5.90
- Analyst Decision
- JAGX Strong Buy
- TENX Strong Buy
- Analyst Count
- JAGX 1
- TENX 3
- Target Price
- JAGX $60.00
- TENX $16.00
- AVG Volume (30 Days)
- JAGX 98.6K
- TENX 40.6K
- Earning Date
- JAGX 08-12-2025
- TENX 08-12-2025
- Dividend Yield
- JAGX N/A
- TENX N/A
- EPS Growth
- JAGX N/A
- TENX N/A
- EPS
- JAGX N/A
- TENX N/A
- Revenue
- JAGX $11,552,000.00
- TENX N/A
- Revenue This Year
- JAGX $22.41
- TENX N/A
- Revenue Next Year
- JAGX $30.00
- TENX N/A
- P/E Ratio
- JAGX N/A
- TENX N/A
- Revenue Growth
- JAGX 13.93
- TENX N/A
- 52 Week Low
- JAGX $2.28
- TENX $2.80
- 52 Week High
- JAGX $110.75
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- JAGX 29.42
- TENX 53.10
- Support Level
- JAGX $2.28
- TENX $5.77
- Resistance Level
- JAGX $2.79
- TENX $5.96
- Average True Range (ATR)
- JAGX 0.16
- TENX 0.32
- MACD
- JAGX 0.11
- TENX 0.01
- Stochastic Oscillator
- JAGX 16.00
- TENX 26.98
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.